在小鼠结核病模型中，评估利福拉齐在联合治疗方案中作为异烟肼-利福平疗法替代药物的效果。
Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
作者信息
Lenaerts A M, Chase S E, Cynamon M H
机构信息
Departments of Medicine, Veterans Affairs Medical Center and State University of New York Upstate Medical University, Syracuse, New York 13210, USA.
出版信息
Antimicrob Agents Chemother. 2000 Nov;44(11):3167-8. doi: 10.1128/AAC.44.11.3167-3168.2000.
The newer rifamycin, rifalazil (RLZ) (previously known as KRM-1648), has been shown in prior experiments to be a highly potent drug against Mycobacterium tuberculosis. In this report, we studied the efficacy of RLZ in combination with pyrazinamide (PZA) and ethambutol (EMB) in a long-term in vivo experiment and compared their activity with the isoniazid (INH)-rifampin (RIF) combination which is presently used in the clinic. Combinations of RLZ with PZA alone or with both PZA and EMB were both found to have sterilizing activities comparable to that of the INH-RIF combination but significantly better activity with respect to relapse of infection. These results suggest that RLZ, or other agents with similar activity, could be combined with available agents to act as a potential alternative drug regimen to the currently used INH-RIF combination.
新型利福霉素利福拉齐（RLZ）（以前称为KRM-1648）在先前实验中已显示出对结核分枝杆菌具有高效力。在本报告中，我们在一项长期体内实验中研究了RLZ与吡嗪酰胺（PZA）和乙胺丁醇（EMB）联合使用的疗效，并将它们的活性与目前临床使用的异烟肼（INH）-利福平（RIF）联合用药进行比较。结果发现，单独使用RLZ与PZA联合或RLZ与PZA和EMB两者联合均具有与INH-RIF联合用药相当的杀菌活性，但在预防感染复发方面活性明显更好。这些结果表明，RLZ或具有类似活性的其他药物可与现有药物联合使用，作为目前使用的INH-RIF联合用药的潜在替代治疗方案。
Zotero 插件